Santos Sanmya Danielle Rodrigues Dos, Bafi Antonio Tonete, Freitas Flávio Geraldo Rezende de, Azevedo Luciano César Pontes de, Machado Flávia Ribeiro
Departamento de Anestesiologia, Dor e Terapia Intensiva, Escola Paulista de Medicina, Universidade Federal de São Paulo - São Paulo (SP), Brasil.
Unidade de Terapia Intensiva, Hospital do Rim - São Paulo (SP), Brasil.
Rev Bras Ter Intensiva. 2017 Oct-Dec;29(4):436-443. doi: 10.5935/0103-507X.20170070.
To define the frequency of cytomegalovirus disease among kidney transplant patients in an intensive care unit in which this complication was suspected and to identify predisposing factors and their possible impact on clinical outcome.
Retrospective observational study in which kidney transplant patients over the age of 18 years were hospitalized for any reason in an intensive care unit with at least one collection of samples to test for the presence of antigenemia or cytomegalovirus via polymerase chain reaction during hospitalization. Cytomegalovirus disease was defined as positive antigenemia or polymerase chain reaction above 500 copies/mL in the presence of symptoms and in the appropriate clinical setting, as judged by the attending physician.
A total of 99 patients were included (age: 53.4 ± 12.8 years, 71.6% male). Cytomegalovirus disease was diagnosed in 39 patients (39.4%). Respiratory symptoms (51%), non-specific clinical worsening (20%) or gastrointestinal symptoms (14%) were the main reasons for exam collection. Transplant time was lower in those with cytomegalovirus disease than in those without this diagnosis (6.5 months and 31.2 months, p = 0.001), along with pulse therapy in the last 6 months (41% and 16.9%, p = 0.008) and previous use of thymoglobulin in the last year (35.9% and 6.8%, p < 0.001). In the logistic regression model, only the transplant time and the use of thymoglobulin were associated with a higher frequency of cytomegalovirus. There was no difference in clinical evolution between patients with and without cytomegalovirus disease.
In kidney transplant patients suspected of cytomegalovirus disease, the prevalence was high. Transplant time less than 6 months, and the use of thymoglobulin in the last year should increase the intensivist's suspicion for this complication.
确定一家重症监护病房中疑似发生该并发症的肾移植患者巨细胞病毒病的发生率,并识别易感因素及其对临床结局的可能影响。
进行回顾性观察研究,纳入18岁以上因任何原因在重症监护病房住院的肾移植患者,这些患者在住院期间至少采集过一次样本,通过聚合酶链反应检测抗原血症或巨细胞病毒的存在。巨细胞病毒病的定义为在出现症状且处于适当临床环境下,抗原血症呈阳性或聚合酶链反应高于500拷贝/mL,由主治医生判断。
共纳入99例患者(年龄:53.4±12.8岁,71.6%为男性)。39例患者(39.4%)被诊断为巨细胞病毒病。呼吸道症状(51%)、非特异性临床病情恶化(20%)或胃肠道症状(14%)是进行检查采集的主要原因。发生巨细胞病毒病的患者移植时间比未诊断出该病的患者短(6.5个月和31.2个月,p = 0.001),同时在过去6个月内接受脉冲治疗的比例也更高(41%和16.9%,p = 0.008),以及在过去一年中曾使用过抗胸腺细胞球蛋白的比例也更高(35.9%和6.8%,p < 0.001)。在逻辑回归模型中,只有移植时间和抗胸腺细胞球蛋白的使用与巨细胞病毒的较高发生率相关。有巨细胞病毒病和无该病的患者临床病程无差异。
在疑似巨细胞病毒病的肾移植患者中,患病率较高。移植时间少于6个月以及过去一年中使用过抗胸腺细胞球蛋白应增加重症监护医生对该并发症的怀疑。